Substantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid nanoparticle (LNP) pioneers. Since this is the most significant happening in this space with respect to IP in 2022, this post will provide an overview of that activity as well as a summary exposure analysis.
Recent Posts
- CAFC Affirms TTAB’s Genericness Test for Color Marks
- AI and the Law: How Companies Can Navigate IP Risk and Seize Opportunity | IPWatchdog Unleashed
- Press Play on American IP: AI Can’t Scratch the Soundtrack to World IP Day
- Other Barks & Bites for Friday, April 25: World IP Day 2025 Celebrates Musicians; Texas A&M to Lead Center for Advanced Aviation Technologies; and Tenth Circuit Affirms Specialty Metals Trade Secret Dismissal
- Judges Seem Frustrated with Judicial Council Arguments in Newman v. Moore Case